Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -18.86 Million USD | 88.59% |
| 2021 | -165.33 Million USD | -86.77% |
| 2020 | -88.52 Million USD | -2.52% |
| 2019 | -86.34 Million USD | -67.75% |
| 2018 | -51.47 Million USD | -84.98% |
| 2017 | -27.82 Million USD | 26.78% |
| 2016 | -38 Million USD | -16.42% |
| 2015 | -32.64 Million USD | -50.35% |
| 2014 | -21.71 Million USD | -75.42% |
| 2013 | -12.37 Million USD | -55.2% |
| 2012 | -7.97 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 Q2 | 10.22 Million USD | 173.82% |
| 2022 Q3 | -9.8 Million USD | -195.91% |
| 2022 Q4 | 14.12 Million USD | 244.09% |
| 2022 Q1 | -13.84 Million USD | 88.47% |
| 2022 FY | -18.86 Million USD | 88.59% |
| 2021 Q1 | -20.39 Million USD | 9.62% |
| 2021 Q4 | -120.02 Million USD | -974.29% |
| 2021 Q2 | -14.31 Million USD | 29.83% |
| 2021 Q3 | -11.17 Million USD | 21.93% |
| 2021 FY | -165.33 Million USD | -86.77% |
| 2020 FY | -88.52 Million USD | -2.52% |
| 2020 Q4 | -22.56 Million USD | 0.74% |
| 2020 Q2 | -20.39 Million USD | 16.59% |
| 2020 Q3 | -22.73 Million USD | -11.49% |
| 2020 Q1 | -24.44 Million USD | -12.51% |
| 2019 Q4 | -21.72 Million USD | -7.07% |
| 2019 Q2 | -24.15 Million USD | -1.96% |
| 2019 FY | -86.34 Million USD | -67.75% |
| 2019 Q1 | -23.68 Million USD | -21.48% |
| 2019 Q3 | -20.29 Million USD | 15.98% |
| 2018 Q4 | -19.49 Million USD | -3.45% |
| 2018 Q2 | -3.07 Million USD | 76.72% |
| 2018 Q1 | -13.2 Million USD | -20.34% |
| 2018 FY | -51.47 Million USD | -84.98% |
| 2018 Q3 | -18.84 Million USD | -512.98% |
| 2017 Q4 | -10.97 Million USD | -80.76% |
| 2017 Q2 | -5.19 Million USD | 7.03% |
| 2017 Q1 | -5.58 Million USD | 41.31% |
| 2017 FY | -27.82 Million USD | 26.78% |
| 2017 Q3 | -6.07 Million USD | -16.88% |
| 2016 Q1 | -9.58 Million USD | -18.77% |
| 2016 FY | -38 Million USD | -16.42% |
| 2016 Q4 | -9.52 Million USD | -11.42% |
| 2016 Q3 | -8.54 Million USD | 17.51% |
| 2016 Q2 | -10.35 Million USD | -8.1% |
| 2015 FY | -32.64 Million USD | -50.35% |
| 2015 Q4 | -8.06 Million USD | 9.35% |
| 2015 Q3 | -8.9 Million USD | -13.84% |
| 2015 Q2 | -7.81 Million USD | 0.51% |
| 2015 Q1 | -7.85 Million USD | -15.0% |
| 2014 Q2 | -5.49 Million USD | -32.35% |
| 2014 FY | -21.71 Million USD | -75.42% |
| 2014 Q4 | -6.83 Million USD | -30.43% |
| 2014 Q3 | -5.23 Million USD | 4.59% |
| 2014 Q1 | -4.14 Million USD | -1.52% |
| 2013 Q4 | -4.08 Million USD | -23.18% |
| 2013 Q3 | -3.31 Million USD | 0.0% |
| 2013 FY | -12.37 Million USD | -55.2% |
| 2012 FY | -7.97 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -2377.739% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -118.559% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 38.645% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 84.8% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -17.34% |
| Better Therapeutics, Inc. | -39.76 Million USD | 52.55% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -2.656% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 47.318% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 47.689% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 83.527% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -739.138% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 74.763% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 68.068% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -215.049% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 11.402% |
| Molecular Templates, Inc. | -8.12 Million USD | -132.226% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -24.305% |
| NexImmune, Inc. | -32.34 Million USD | 41.671% |
| Orgenesis Inc. | -55.36 Million USD | 65.922% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 25.322% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -24081.909% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -3.151% |
| Scopus BioPharma Inc. | -11.6 Million USD | -62.5% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 96.707% |
| Statera Biopharma, Inc. | -174.4 Million USD | 89.183% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -425.808% |
| Trevena, Inc. | -40.28 Million USD | 53.173% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -33036.614% |
| Vaccinex, Inc. | -20.25 Million USD | 6.839% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -1495.957% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 63.05% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -142.581% |